Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:KZR NASDAQ:MCRB NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.34-3.7%$2.92$1.60▼$5.89$131.03M-0.34146,255 shs107,663 shsKZRKezar Life Sciences$4.31-3.6%$4.37$3.62▼$9.18$32.66M0.672,715 shs53,176 shsMCRBSeres Therapeutics$14.53+8.4%$9.61$6.53▼$29.40$117.01M2.75152,254 shs247,698 shsPLXProtalix BioTherapeutics$1.51-2.6%$1.52$0.82▼$3.10$120.21M-0.23879,348 shs287,127 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux-3.61%+2.06%+24.82%+20.49%+59.91%KZRKezar Life Sciences+3.95%+0.22%+0.90%-4.89%-32.39%MCRBSeres Therapeutics+2.37%-4.83%+59.14%+32.94%-48.06%PLXProtalix BioTherapeutics-3.13%+3.33%+1.31%-45.61%+34.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNLXGenelux1.2316 of 5 stars3.60.00.00.02.70.00.0KZRKezar Life Sciences4.1969 of 5 stars3.22.00.04.62.23.30.6MCRBSeres Therapeutics3.5046 of 5 stars2.91.00.04.64.00.80.0PLXProtalix BioTherapeutics2.9429 of 5 stars3.53.00.00.02.40.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.20Buy$17.75431.44% UpsideKZRKezar Life Sciences 2.33Hold$39.50816.47% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67407.00% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00893.38% UpsideCurrent Analyst Ratings BreakdownLatest KZR, GNLX, MCRB, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/16/2025KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K12,611.84N/AN/A$0.76 per share4.39KZRKezar Life Sciences$7M4.50N/AN/A$16.02 per share0.27MCRBSeres Therapeutics$126.32M1.00N/AN/A$1.61 per share9.02PLXProtalix BioTherapeutics$59.76M2.01$0.08 per share17.80$0.47 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/6/2025 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.04N/A4.87N/A-21.03%-30.89%-11.74%N/ALatest KZR, GNLX, MCRB, and PLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/AGNLXGenelux-$0.22N/AN/AN/AN/AN/A8/12/2025Q2 2025KZRKezar Life Sciences-$2.25N/AN/AN/AN/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72N/AN/AN/AN/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.674.67KZRKezar Life Sciences0.047.097.09MCRBSeres TherapeuticsN/A2.112.11PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%KZRKezar Life Sciences67.90%MCRBSeres Therapeutics59.34%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipGNLXGenelux9.30%KZRKezar Life Sciences10.40%MCRBSeres Therapeutics4.70%PLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.76 million34.25 millionNot OptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableKZR, GNLX, MCRB, and PLX HeadlinesRecent News About These CompaniesProtalix BioTherapeutics Names Gilad Mamlok Chief Financial OfficerJuly 21, 2025 | marketwatch.comProtalix BioTherapeutics Names SVP and CFOJuly 21, 2025 | contractpharma.comCProtalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerJuly 21, 2025 | finanznachrichten.deProtalix BioTherapeutics welcomes new finance chiefJuly 21, 2025 | proactiveinvestors.comPLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...July 10, 2025 | marketwatch.comProtalix BioTherapeutics (NYSE:PLX) Shares Up 3.4% - Still a Buy?July 10, 2025 | marketbeat.comProtalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitutionJune 30, 2025 | proactiveinvestors.comProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | finance.yahoo.comPLX: First Quarter ResultsMay 13, 2025 | msn.comEarnings call transcript: Protalix Q1 2025 results miss forecasts, stock plungesMay 10, 2025 | uk.investing.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 10, 2025 | finanznachrichten.deProtalix BioTherapeutics Q1 Earnings PreviewMay 10, 2025 | msn.com1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings PreviewMay 10, 2025 | benzinga.comProtalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comProtalix eyes Phase II gout trial later this year following solid Q1 revenue growthMay 9, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 9, 2025 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025May 6, 2025 | seekingalpha.comWhy Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%April 15, 2025 | aaii.comAProtalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising PipelineApril 10, 2025 | seekingalpha.comProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025March 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZR, GNLX, MCRB, and PLX Company DescriptionsGenelux NASDAQ:GNLX$3.34 -0.13 (-3.75%) Closing price 04:00 PM EasternExtended Trading$3.33 -0.01 (-0.30%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Kezar Life Sciences NASDAQ:KZR$4.31 -0.16 (-3.58%) Closing price 04:00 PM EasternExtended Trading$4.31 0.00 (0.00%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Seres Therapeutics NASDAQ:MCRB$14.53 +1.13 (+8.43%) Closing price 04:00 PM EasternExtended Trading$14.66 +0.13 (+0.86%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Protalix BioTherapeutics NYSE:PLX$1.51 -0.04 (-2.58%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.00 (+0.33%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
